Physician
Pain Relief Centers
Pain Relief Centers was paid $8.74M by Medicaid between Feb 2019 and Dec 2024, across 29 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 20% of everything it billed.
33Billing provider infoPAIN RELIEF CENTERS
LOUISVILLE, KY 40216
LOUISVILLE, KY 40216
33aNPI1457851578assigned 02/15/2018
33bProvider typePain Medicine (Anesthesiology) Physician
28Total paid$8.74M
24GClaims124,984
24DCodes billed29
24AFirst – last monthFeb 2019 – Dec 2024
Compared with peers
Next to other Pain Medicine (Anesthesiology) Physician providers in Kentucky
Rank by total paid#1 of 21
Median peer was paid$90K
This provider vs. median97×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 16,961 | $1.09M | |
| 2020 | 14,495 | $892K | |
| 2021 | 24,770 | $1.84M | |
| 2022 | 25,571 | $1.79M | |
| 2023 | 23,826 | $1.76M | |
| 2024incomplete | 19,361 | $1.38M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 20% | 39,107 | 34,888 | $1.71M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 14% | 13,556 | 12,715 | $1.20M |
| 64635 | 9.9% | 3,529 | 3,128 | $868K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 8.8% | 15,916 | 14,909 | $769K |
| 64636 | 7.9% | 7,020 | 3,131 | $695K | |
| L0650 | Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | 6.4% | 507 | 471 | $564K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 5.2% | 2,490 | 2,316 | $455K |
| 64493 | 4.5% | 3,916 | 3,329 | $394K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 3.2% | 3,350 | 3,056 | $279K |
| 62323 | 3.0% | 1,983 | 1,825 | $264K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.9% | 8,297 | 7,276 | $249K |
| 64494 | 2.3% | 4,125 | 3,328 | $204K |
17 more codes
| 64495 | 2.2% | 4,124 | $195K | |
| 64633 | 2.0% | 718 | $177K | |
| 64634 | 1.7% | 1,397 | $147K | |
| 64490 | 1.4% | 1,101 | $122K | |
| 20610 | 1.0% | 2,687 | $91K | |
| L1833 | Knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated, off-the shelf | <1% | 122 | $83K |
| 99152 | <1% | 3,406 | $71K | |
| 64491 | <1% | 1,153 | $62K | |
| 64492 | <1% | 1,145 | $60K | |
| 77002 | <1% | 1,712 | $58K | |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | <1% | 442 | $12K |
| 20553 | <1% | 160 | $6K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,762 | $5K |
| 99153 | Mod sedat endo service >5yrs | <1% | 189 | $1K |
| 01938 | <1% | 14 | $389.75 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 27 | $10.05 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 29 | $5.12 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKLICKOVICH, ROBERT (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Robert J Klickovich MD | Florence, KY | $16K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.